معرفی
Peter Ellmark is an Adjunct Professor affiliated with the Department of Immunotechnology at Lund University and serves as a Researcher at the Lund University Cancer Centre (LUCC). His work bridges academic research and translational medicine through collaborations with industry and clinical teams.
- Academic Affiliation: Department of Immunotechnology, Lund University
- Clinical Research: Lund University Cancer Centre
Ellmark specializes in the discovery and development of monoclonal and bispecific antibodies with a focus on immuno-oncology applications. His research leverages antigen-presenting cells via targets like CD40 and 4-1BB, aiming to enhance anti-tumor immune responses. He has advanced four antibody-based drug candidates into clinical development, emphasizing co-stimulatory receptors and immune checkpoint inhibitors.
Recent publications highlight his work on CD40-targeted therapies for pancreatic cancer (2024), coiled coil-based antigen delivery systems (2025), and next-generation 4-1BB agonists (2024-2025). These studies span oncology, immunology, and biological therapy, often involving phase I/II clinical trials and tumor microenvironment modulation.
He supervises doctoral projects, including the Impact of CD40 therapies on the tumor microenvironment (2023-2027), and contributes to multidisciplinary collaborations across 15+ countries. His research aligns with the UN Sustainable Development Goal for Engineering and Technology.
